Nasdaq
$156.10▲ 0.01%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $193.81BShares out 12.400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
33- 10.16After-hours26.10.17 05:174Ownership#●●●
GILEAD SCIENCES, INC.
Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc., reported an insider transaction involving the sale of company stock on October 15, 2026. This filing serves as a standard disclosure of changes in executive beneficial ownership.…more
$156.10+0.01%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.16After-hours26.10.17 05:124Ownership
GILEAD SCIENCES, INC.
Johanna Mercier, an executive at Gilead Sciences, reported a change in beneficial ownership of securities on October 15, 2026. This filing is a standard Form 4 disclosure regarding insider stock holdings.…more
$156.10+0.01%vs prev closeView filingShare - 10.15After-hours26.10.16 05:22144Ownership
GILEAD SCIENCES, INC.
Johanna Mercier, an insider at Gilead Sciences, Inc., has filed a Form 144 regarding the proposed sale of company shares. This is a standard regulatory filing disclosing an insider's plan to dispose of their holdings.…more
$156.10+0.01%vs prev closeView filingShare
32 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoAfter-hours26.10.23 05:07#●●●#●●●
Gilead Sciences to Acquire PepStar Therapeutics for $1.275B
Gilead Sciences has entered a definitive agreement to acquire PepStar Therapeutics' oral IL-23R inhibitor program for $1.275 billion in cash. The transaction is expected to close in the fourth quarter of 2026 as part of Gilead's pipeline expansion.…more
$156.10+0.01%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 3d agoPre-market26.10.22 19:48
●●●●●●●● ●●●●● ●●●●●●
BioNTech and Gilead Sciences have entered a collaboration to evaluate a combination of pumitamig and sacituzumab govitecan in a Phase 3 trial for triple-negative breast cancer. The partnership aims to adapt the trial to current standards of care to potentially improve patient outcomes.…more
$156.10+0.01%vs prev closeShareBenzinga - 5d agoRegular26.10.20 03:07
●●●●●●●● ●●●●● ●●●●●●
Gilead Sciences announced that its investigational oral treatment for ulcerative colitis met primary efficacy goals in a Phase 2 trial. The company is now proceeding with further analyses to evaluate long-term maintenance outcomes for the drug candidate.…more
$156.10+0.01%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report